Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 117 participants.

Also called NCT07583147

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose basic science
Phase
Phase 2
Enrolled
  • 117 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07583147
  • EU CT 2025-521923-58-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07583147. Allocation not applicable; no masking; primary purpose basic science. Start 2026-06 (anticipated); primary completion 2029-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.
Acronym
INFINITE
Condition
Intracerebral Hemorrhage
Intervention (Drug)
TEP with 18F-DPA-714 injection
Lead sponsor
University Hospital, Toulouse (class: other)

Record details

Record id
cardio:ct-nct07583147
Content hash
e64307921b5cef18d0c8c2602be357351458ed7890100ce5a901365660303b99